371 research outputs found

    Elevated AKR1C3 expression promotes prostate cancer cell survival and prostate cell-mediated endothelial cell tube formation: implications for prostate cancer progressioan

    Get PDF
    <p>Abstract</p> <p>Background</p> <p>Aldo-keto reductase (AKR) 1C family member 3 (AKR1C3), one of four identified human AKR1C enzymes, catalyzes steroid, prostaglandin, and xenobiotic metabolism. In the prostate, AKR1C3 is up-regulated in localized and advanced prostate adenocarcinoma, and is associated with prostate cancer (PCa) aggressiveness. Here we propose a novel pathological function of AKR1C3 in tumor angiogenesis and its potential role in promoting PCa progression.</p> <p>Methods</p> <p>To recapitulate elevated AKR1C3 expression in cancerous prostate, the human PCa PC-3 cell line was stably transfected with an AKR1C3 expression construct to establish PC3-AKR1C3 transfectants. Microarray and bioinformatics analysis were performed to identify AKR1C3-mediated pathways of activation and their potential biological consequences in PC-3 cells. Western blot analysis, reverse transcription-polymerase chain reaction (RT-PCR), enzyme-linked immunosorbent assay (ELISA), and an <it>in vitro </it>Matrigel angiogenesis assays were applied to validate the pro-angiogenic activity of PC3-AKR1C3 transfectants identified by bioinformatics analysis.</p> <p>Results</p> <p>Microarray and bioinformatics analysis suggested that overexpression of AKR1C3 in PC-3 cells modulates estrogen and androgen metabolism, activates insulin-like growth factor (IGF)-1 and Akt signaling pathways, as well as promotes tumor angiogenesis and aggressiveness. Levels of IGF-1 receptor (IGF-1R) and Akt activation as well as vascular endothelial growth factor (VEGF) expression and secretion were significantly elevated in PC3-AKR1C3 transfectants in comparison to PC3-mock transfectants. PC3-AKR1C3 transfectants also promoted endothelial cell (EC) tube formation on Matrigel as compared to the AKR1C3-negative parental PC-3 cells and PC3-mock transfectants. Pre-treatment of PC3-AKR1C3 transfectants with a selective IGF-1R kinase inhibitor (AG1024) or a non-selective phosphoinositide 3-kinases (PI3K) inhibitor (LY294002) abolished ability of the cells to promote EC tube formation.</p> <p>Conclusions</p> <p>Bioinformatics analysis followed by functional genomics demonstrated that AKR1C3 overexpression promotes angiogenesis and aggressiveness of PC-3 cells. These results also suggest that AKR1C3-mediated tumor angiogenesis is regulated by estrogen and androgen metabolism with subsequent IGF-1R and Akt activation followed by VEGF expression in PCa cells.</p

    The effects of long-term total parenteral nutrition on gut mucosal immunity in children with short bowel syndrome: a systematic review

    Get PDF
    BACKGROUND: Short bowel syndrome (SBS) is defined as the malabsorptive state that often follows massive resection of the small intestine. Most cases originate in the newborn period and result from congenital anomalies. It is associated with a high morbidity, is potentially lethal and often requires months, sometimes years, in the hospital and home on total parenteral nutrition (TPN). Long-term survival without parenteral nutrition depends upon establishing enteral nutrition and the process of intestinal adaptation through which the remaining small bowel gradually increases its absorptive capacity. The purpose of this article is to perform a descriptive systematic review of the published articles on the effects of TPN on the intestinal immune system investigating whether long-term TPN induces bacterial translocation, decreases secretory immunoglobulin A (S-IgA), impairs intestinal immunity, and changes mucosal architecture in children with SBS. METHODS: The databases of OVID, such as MEDLINE and CINAHL, Cochran Library, and Evidence-Based Medicine were searched for articles published from 1990 to 2001. Search terms were total parenteral nutrition, children, bacterial translocation, small bowel syndrome, short gut syndrome, intestinal immunity, gut permeability, sepsis, hyperglycemia, immunonutrition, glutamine, enteral tube feeding, and systematic reviews. The goal was to include all clinical studies conducted in children directly addressing the effects of TPN on gut immunity. RESULTS: A total of 13 studies were identified. These 13 studies included a total of 414 infants and children between the ages approximately 4 months to 17 years old, and 16 healthy adults as controls; and they varied in design and were conducted in several disciplines. The results were integrated into common themes. Five themes were identified: 1) sepsis, 2) impaired immune functions: In vitro studies, 3) mortality, 4) villous atrophy, 5) duration of dependency on TPN after bowel resection. CONCLUSION: Based on this exhaustive literature review, there is no direct evidence suggesting that TPN promotes bacterial overgrowth, impairs neutrophil functions, inhibits blood's bactericidal effect, causes villous atrophy, or causes to death in human model. The hypothesis relating negative effects of TPN on gut immunity remains attractive, but unproven. Enteral nutrition is cheaper, but no safer than TPN. Based on the current evidence, TPN seems to be safe and a life saving solution

    An overview of concepts and approaches used in estimating the burden of congenital disorders globally.

    Get PDF
    Congenital disorders are an important cause of pregnancy loss, premature death and life-long disability. A range of interventions can greatly reduce their burden, but the absence of local epidemiological data on their prevalence and the impact of interventions impede policy and service development in many countries. In an attempt to overcome these deficiencies, we have developed a tool-The Modell Global Database of Congenital Disorders (MGDb) that combines general biological principles and available observational data with demographic data, to generate estimates of the birth prevalence and effects of interventions on mortality and disability due to congenital disorders. MGDb aims to support policy development by generating country, regional and global epidemiological estimates. Here we provide an overview of the concepts and methodological approach used to develop MGDb

    Measurements of charged current lepton universality and |Vus| using tau lepton decays to e- (e) ( ), - ( ) ( ), - ( ), and K- ( ).

    Get PDF
    9 pages, 12 encapsulated postscript figures, submitted to Physical Review LettersInternational audienceUsing 467 fb1fb^{-1} of e+ee^+e^- annihilation data collected with the BaBar detector, we measure B(τμνˉμντ)B(τeνˉeντ)=(0.9796±0.0016±0.0036)\frac{{\cal{B}}(\tau^- \to \mu^- \bar{\nu}_\mu \nu_\tau)}{{\cal{B}}(\tau^- \to e^- \bar{\nu}_e \nu_\tau)} = (0.9796 \pm 0.0016 \pm 0.0036), B(τπντ)B(τeνˉeντ)=(0.5945±0.0014±0.0061)\frac{{\cal{B}}(\tau^- \to \pi^- \nu_\tau)}{{\cal{B}}(\tau^- \to e^- \bar{\nu}_e \nu_\tau)} = (0.5945 \pm 0.0014 \pm 0.0061), and \frac{{\cal{B}}(\tau^- \to \K^- \nu_\tau)}{{\cal{B}}(\tau^- \to e^- \bar{\nu}_e \nu_\tau)} = (0.03882 \pm 0.00032 \pm 0.00057), where the uncertainties are statistical and systematic, respectively. From these precision measurements we test the Standard Model assumption of μ\mu-ee and τ\tau-μ\mu charged current lepton universality and also obtain a value for Vus=0.2255±0.0024|V_{us}| = 0.2255 \pm 0.0024, which is consistent with the prediction from the unitarity of the Cabibbo-Kobayashi-Maskawa matrix

    Improved Limits on the Lepton-Flavor Violating Decays τ−→l−l+l−

    Full text link
    A search for the neutrinoless, lepton-flavor violating decay of the tau lepton into three charged leptons has been performed using 376     fb − 1 of data collected at an e + e − center-of-mass energy around 10.58 GeV with the BABAR detector at the SLAC PEP-II storage rings. In all six decay modes considered, the numbers of events found in data are compatible with the background expectations. Upper limits on the branching fractions are set in the range ( 4 - 8 ) × 10 − 8 at 90% confidence level

    Middle cretaceous foraminifera and biostratigraphy of Western Siberia

    Get PDF
    7 pages, 4 postscript figures, submitted to PRLWe present partial branching fractions for inclusive charmless semileptonic B decays Bbar --> X_u ell nubar, and the determination of the CKM matrix element |V_{ub}|. The analysis is based on a sample of 383 million Y(4S) decays into B Bbar pairs collected with the BaBar detector at the PEP-II e+ e- storage rings. We select events using either the invariant mass M_X of the hadronic system, the invariant mass squared, q^2, of the lepton and neutrino pair, the kinematic variable P_+ or one of their combinations. We then determine partial branching fractions in limited regions of phase space: Delta B = (1.18 +- 0.09_{stat.} +- 0.07_{sys.} +- 0.01_{theo.}) x 10^{-3} (M_X 8 GeV^2/c^4). Corresponding values of |V_{ub}| are extracted using several theoretical calculations

    Branching fraction measurements of B+->rho(+)gamma, B-0 ->rho(0)gamma, and B-0 ->omega gamma

    Get PDF
    We present a study of the decays B+->rho(+)gamma, B-0 ->rho(0)gamma, and B-0 ->omega gamma. The analysis is based on data containing 347x10(6) B (B) over bar events recorded with the BABAR detector at the PEP-II asymmetric B factory. We measure the branching fractions B(B+->rho(+)gamma)=(1.10(-0.33)(+0.37)+/- 0.09)x10(-6) and B(B-0 ->rho(0)gamma)=(0.79(-0.20)(+0.22)+/- 0.06)x10(-6), and set a 90% C.L. upper limit B(B-0 ->omega gamma)(rho/omega)gamma)=(1.25(-0.24)(+0.25)+/- 0.09)x10(-6), from which we determine vertical bar V-td/V-ts vertical bar=0.200(-0.020)(+0.021)+/- 0.015, where the first uncertainty is experimental and the second is theoretical
    corecore